When compared to high-dose ICS treatment paired with a placebo, the monoclonal antibody with medium-dose ICS treatment reduced severe asthma exacerbations by 70% (0.273 vs 0.899 per year, P<0.0001 ...

Of the 1,505 patients in the LIBERTY ASTHMA QUEST study, 282 had fungal sensitization at baseline; of those, 155 were on high-dose ICS (placebo, 63; dupilumab, 92) and 127 were on medium-dose ICS ...

Maintenance of asthma was defined as no asthma exacerbations since the previous visit, no increase in Asthma Control Questionnaire (ACQ-5), and no significant increase in ICS-formoterol reliever ...

LOUISVILLE, Ky. — Patients with asthma faced high risks for exacerbations despite their maintenance medication or disease severity, reported researchers at the American College of Allergy ...

Stepping down to as-needed ICS/FABA maintained asthma stability while significantly reducing steroid exposure in individuals ...

TUESDAY, Oct. 29, 2024 (HealthDay News) -- For patients with asthma, inhaled corticosteroids (ICS) combined with short-acting β agonists (SABA) and ICS combined with the long-acting β agonist ...

Meeting Coverage > ERS Benralizumab Allows Inhaled Corticosteroid Taper for Asthma Patients — Most were able to reduce doses without increase in symptoms, exacerbations, trial finds ...

The researchers recruited 208 adult patients with controlled severe eosinophilic asthma on high-dose ICS following the initiation of benralizumab. The mean age of participants was 57.7; 47% were ...

Conversely, ICS use is controversial in COPD and only the medium doses of ICS in fixed combinations ICS + LABA inhalers are FDA-approved to control symptoms and reduce acute exacerbations – that ...

TUESDAY, Sept. 10, 2024 (HealthDay News) -- For patients with severe asthma with an eosinophilic phenotype, depemokimab reduces the annualized rate of exacerbations, according to a study published ...

Patients with mild to moderate asthma who were previously treated with as-needed SABA alone or with low-dose ICS maintenance therapy plus as-needed SABA were randomly assigned to receive Airsupra ...

ICS combined with short-acting β agonists and ICS combined with the long-acting β agonist formoterol are each associated with reduced asthma exacerbations compared with SABA alone.